TW201726651A - ２，３，４，５－四氫吡啶－６－胺衍生物 - Google Patents

２，３，４，５－四氫吡啶－６－胺衍生物 Download PDF

Info

Publication number
TW201726651A
TW201726651A TW105130403A TW105130403A TW201726651A TW 201726651 A TW201726651 A TW 201726651A TW 105130403 A TW105130403 A TW 105130403A TW 105130403 A TW105130403 A TW 105130403A TW 201726651 A TW201726651 A TW 201726651A
Authority
TW
Taiwan
Prior art keywords
alkyloxy
alkyl
compound
group
cyclopropyl
Prior art date
Application number
TW105130403A
Other languages
English (en)
Chinese (zh)
Inventor
弗雷德里克 倫巴烏茲
亨里克斯 吉森
司凡 凡布蘭特
蘇瑞茲 安德烈斯 卓班克
Original Assignee
健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 健生藥品公司 filed Critical 健生藥品公司
Publication of TW201726651A publication Critical patent/TW201726651A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW105130403A 2015-09-23 2016-09-21 ２，３，４，５－四氫吡啶－６－胺衍生物 TW201726651A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15186394 2015-09-23
EP16172005 2016-05-30

Publications (1)

Publication Number Publication Date
TW201726651A true TW201726651A (zh) 2017-08-01

Family

ID=56985626

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105130403A TW201726651A (zh) 2015-09-23 2016-09-21 ２，３，４，５－四氫吡啶－６－胺衍生物

Country Status (14)

Country Link
US (1) US20180334447A1 (enExample)
EP (1) EP3353163B1 (enExample)
JP (1) JP2018527387A (enExample)
KR (1) KR20180053357A (enExample)
CN (1) CN108026069A (enExample)
AU (1) AU2016328589A1 (enExample)
BR (1) BR112018005591A2 (enExample)
CA (1) CA2995161A1 (enExample)
EA (1) EA035026B1 (enExample)
HK (1) HK1254800A1 (enExample)
IL (1) IL258217A (enExample)
MX (1) MX2018003565A (enExample)
TW (1) TW201726651A (enExample)
WO (1) WO2017050978A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022511167A (ja) * 2018-04-23 2022-01-31 塩野義製薬株式会社 選択的ｂａｃｅ１阻害活性を有する二環式複素環誘導体
KR20210003872A (ko) 2018-04-27 2021-01-12 시오노기 앤드 컴파니, 리미티드 선택적 bace1 억제 활성을 갖는 테트라하이드로피라노옥사진 유도체
CN114380736B (zh) * 2020-10-21 2023-10-03 复旦大学 一种2,3,4,5-四氢吡啶类化合物的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
US20120258961A1 (en) * 2009-12-24 2012-10-11 Shionogi & Co., Ltd. 4-amino-1,3-thiazine or oxazine derivative
US8673894B2 (en) 2010-05-07 2014-03-18 Hoffmann-La Roche Inc. 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
EP2580200B1 (en) * 2010-06-09 2016-09-14 Janssen Pharmaceutica, N.V. 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
WO2012057247A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
US8815841B2 (en) 2011-02-18 2014-08-26 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
WO2014059185A1 (en) 2012-10-12 2014-04-17 Amgen Inc. Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
TW201446758A (zh) 2013-03-01 2014-12-16 Amgen Inc 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途
PE20161225A1 (es) 2014-02-19 2016-12-04 H Lundbeck As 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer

Also Published As

Publication number Publication date
JP2018527387A (ja) 2018-09-20
KR20180053357A (ko) 2018-05-21
EA201890769A1 (ru) 2018-09-28
EA035026B1 (ru) 2020-04-20
HK1254800A1 (zh) 2019-07-26
US20180334447A1 (en) 2018-11-22
CN108026069A (zh) 2018-05-11
EP3353163B1 (en) 2020-02-05
AU2016328589A1 (en) 2018-03-01
WO2017050978A1 (en) 2017-03-30
CA2995161A1 (en) 2017-03-30
EP3353163A1 (en) 2018-08-01
IL258217A (en) 2018-05-31
MX2018003565A (es) 2018-06-18
BR112018005591A2 (pt) 2018-10-09

Similar Documents

Publication Publication Date Title
CN114945566A (zh) 作为钠通道调节剂的取代四氢呋喃
KR100896838B1 (ko) 모폴린 화합물
KR20210107046A (ko) 거대고리 화합물 및 질환 치료에서 이들의 용도
JP2022547952A (ja) Ｂｒｄ９二機能性分解誘導薬及びその使用方法
EP3433258B1 (en) Pyrimidines and variants thereof, and uses therefor
TW201730175A (zh) Ｔｌｒ７／８拮抗劑及其用途
CN103415521A (zh) 用作β分泌酶（BACE）抑制剂的3,4-二氢-吡咯并[1,2-a]吡嗪-1-基胺衍生物
CN107148409B (zh) 经取代的二环化合物
WO2020063824A1 (zh) 硝羟喹啉前药及其用途
CN102971307A (zh) 作为kv7钾通道开放剂的哌啶基嘧啶酰胺
TW202017916A (zh) 新穎緩激肽ｂ２受體拮抗劑及其用途
CN113698390B (zh) 用作ret激酶抑制剂的化合物及其应用
JP2022502444A (ja) ３−アザビシクロ［３，１，１］ヘプタン誘導体及びこれを含む薬学的組成物
JPWO2020128925A5 (enExample)
JP2020509033A (ja) ブロモドメイン阻害薬としてのピラゾール誘導体
TW201726651A (zh) ２，３，４，５－四氫吡啶－６－胺衍生物
AU2020394597A1 (en) 1,2,4-oxadiazole derivatives as liver X receptor agonists
CN115515959A (zh) 用作tead结合剂的三环杂环
TW202333697A (zh) Ｗｎｔ通路抑制劑化合物
TW202304906A (zh) 高活性hpk1激酶抑制劑
CN107428682A (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
TWI810547B (zh) Pd-l1拮抗劑化合物
JP2023175554A (ja) 医薬組成物及びオートファジー活性化剤
KR20070022753A (ko) 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도
HK40061670A (en) Compounds and compositions for treating conditions associated with apj receptor activity